1.2M
Downloads
942
Episodes
Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com
Episodes
4 days ago
4 days ago
Dr. Jack Cush reviews the news, journal reports and lupus highlights from the past week on RheumNow.com. Triple positivity, the gut and CRPS, and hope for better outcomes with Vitamin D therapy.
4 days ago
4 days ago
In this first webinar of RheumNow's Lupus Unlocked campaign, Journal Club discussed two articles:
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. Furie R, et al. NEJM. 2025 Feb 7. doi: 10.1056
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1) Rovin BH. Lancet. 2021 May 29;397(10289)
Speakers:
Brad Rovin, MD
Richard Furie, MD
Jack Cush, MD
Friday May 02, 2025
Friday May 02, 2025
Dr. Jack Cush reviews the news, articles and drug approvals from the past week on RheumNow.com. This podcast marks the beginning of our Lupus Campaign called "Lupus Unlocked: Keys to Mastery". This months campaign on Lupus is sponsored by Aurinia.
Thursday May 01, 2025
Thursday May 01, 2025
Listen as coinvestigator and rheumatologist Dr. Andrea Rubbert-Roth reviews this Phase 3 trial of a JAKi in patients with giant cell arteritis. Dr. Rubbert-Roth discusses the latest results, including efficacy and safety outcomes.
Saturday Apr 26, 2025
Saturday Apr 26, 2025
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Should we believe the reviews and metanalyses?
Friday Apr 18, 2025
Friday Apr 18, 2025
Dr. Jack Cush reviews the news and Journal reports from this week on RheumNow.com. Osteoarthritis patients have unique risks and synovial fluid WBC numbers can tell you when to worry about septic arthritis in gout and pseudogout patients.
Friday Apr 11, 2025
Friday Apr 11, 2025
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com
Friday Apr 04, 2025
Friday Apr 04, 2025
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
**Correction: a Tweet from 3/18 podcast, had incorrect information. Late Breaking abstract from 2025 Amer. Acad. Dermatology (AAD) on the Phase 3 ICONIC-LEAD study showed J&J's oral IL-23 inhibitor (icotrokinra) was superior to PLACEBO (not deucravacitinib as reported) in skin clearance (65% vs 8%) & PASI90 (50% v 4%) at Wk 16 (NOT 15) in 684 moderate-to-severe plaque PsO pts https://buff.ly/dMbTbML
Tuesday Apr 01, 2025
Tuesday Apr 01, 2025
Rheumatologist Dr. Walter Maksymowych discusses the role of biomarkers in RA care, with a focus on 14-3-3eta as a modifiable marker for diagnosis and monitoring disease progression.
Friday Mar 28, 2025
Friday Mar 28, 2025
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com